206 related articles for article (PubMed ID: 30605832)
1. Triptolide-targeted delivery methods.
Xu H; Liu B
Eur J Med Chem; 2019 Feb; 164():342-351. PubMed ID: 30605832
[TBL] [Abstract][Full Text] [Related]
2. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms.
Zhang YQ; Shen Y; Liao MM; Mao X; Mi GJ; You C; Guo QY; Li WJ; Wang XY; Lin N; Webster TJ
Nanomedicine; 2019 Jan; 15(1):86-97. PubMed ID: 30244085
[TBL] [Abstract][Full Text] [Related]
3. Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics.
Yang M; Gu Y; Yang D; Tang X; Liu J
J Nanobiotechnology; 2017 Dec; 15(1):88. PubMed ID: 29202753
[TBL] [Abstract][Full Text] [Related]
4. Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation.
He QL; Minn I; Wang Q; Xu P; Head SA; Datan E; Yu B; Pomper MG; Liu JO
Angew Chem Int Ed Engl; 2016 Sep; 55(39):12035-9. PubMed ID: 27574181
[TBL] [Abstract][Full Text] [Related]
5. Triptolide-nanoliposome-APRPG, a novel sustained-release drug delivery system targeting vascular endothelial cells, enhances the inhibitory effects of triptolide on laser-induced choroidal neovascularization.
Lai K; Li Y; Gong Y; Li L; Huang C; Xu F; Zhong X; Jin C
Biomed Pharmacother; 2020 Nov; 131():110737. PubMed ID: 32932044
[TBL] [Abstract][Full Text] [Related]
6. Triptolide: Medicinal chemistry, chemical biology and clinical progress.
Hou W; Liu B; Xu H
Eur J Med Chem; 2019 Aug; 176():378-392. PubMed ID: 31121546
[TBL] [Abstract][Full Text] [Related]
7. Triptolide-loaded nanoparticles targeting breast cancer in vivo with reduced toxicity.
Zheng W; Wang C; Ding R; Huang Y; Li Y; Lu Y
Int J Pharm; 2019 Dec; 572():118721. PubMed ID: 31626922
[TBL] [Abstract][Full Text] [Related]
8. Cubic and hexagonal liquid crystals as drug carriers for the transdermal delivery of triptolide.
Shan QQ; Jiang XJ; Wang FY; Shu ZX; Gui SY
Drug Deliv; 2019 Dec; 26(1):490-498. PubMed ID: 31081409
[TBL] [Abstract][Full Text] [Related]
9. Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.
Cai XJ; Fei WD; Xu YY; Xu H; Yang GY; Cao JW; Ni JJ; Wang Z
Drug Deliv Transl Res; 2020 Feb; 10(1):93-107. PubMed ID: 31418132
[TBL] [Abstract][Full Text] [Related]
10. Preparation and anti-inflammatory activity of triptolide ethosomes in an erythema model.
Chen JG; Liu YF; Gao TW
J Liposome Res; 2010 Dec; 20(4):297-303. PubMed ID: 20102297
[TBL] [Abstract][Full Text] [Related]
11. Identification of in vivo and in vitro metabolites of triptolide by liquid chromatography-tandem mass spectrometry.
Peng ZH; Wang JJ; Du P; Chen Y
J Pharm Biomed Anal; 2012 Nov; 70():624-30. PubMed ID: 22824635
[TBL] [Abstract][Full Text] [Related]
12. Renal targeted delivery of triptolide by conjugation to the fragment peptide of human serum albumin.
Yuan ZX; Wu XJ; Mo J; Wang YL; Xu CQ; Lim LY
Eur J Pharm Biopharm; 2015 Aug; 94():363-71. PubMed ID: 26117184
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, Characterization, and Evaluation of Triptolide Cell-Penetrating Peptide Derivative for Transdermal Delivery of Triptolide.
Tian T; Song Y; Li K; Sun Y; Wang Q
Mol Pharm; 2018 Feb; 15(2):560-570. PubMed ID: 29307194
[TBL] [Abstract][Full Text] [Related]
14. Triptolide and its expanding multiple pharmacological functions.
Liu Q
Int Immunopharmacol; 2011 Mar; 11(3):377-83. PubMed ID: 21255694
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats.
Zhang C; Peng F; Liu W; Wan J; Wan C; Xu H; Lam CW; Yang X
Int J Nanomedicine; 2014; 9():1049-63. PubMed ID: 24591827
[TBL] [Abstract][Full Text] [Related]
16. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide.
Mei Z; Chen H; Weng T; Yang Y; Yang X
Eur J Pharm Biopharm; 2003 Sep; 56(2):189-96. PubMed ID: 12957632
[TBL] [Abstract][Full Text] [Related]
17. Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs free triptolide in rats.
Xue M; Zhao Y; Li XJ; Jiang ZZ; Zhang L; Liu SH; Li XM; Zhang LY; Yang SY
Eur J Pharm Sci; 2012 Nov; 47(4):713-7. PubMed ID: 22677813
[TBL] [Abstract][Full Text] [Related]
18. Influence of astragaloside IV on pharmacokinetics of triptolide in rats and its potential mechanism.
Gao J; Zeng X; Zhao W; Chen D; Liu J; Zhang N; Duan X
Pharm Biol; 2020 Dec; 58(1):253-256. PubMed ID: 32233814
[No Abstract] [Full Text] [Related]
19. Synthesis, characterization and in vitro evaluation of triptolide-lysozyme conjugate for renal targeting delivery of triptolide.
Zheng Q; Gong T; Sun X; Zhang ZR
Arch Pharm Res; 2006 Dec; 29(12):1164-70. PubMed ID: 17225468
[TBL] [Abstract][Full Text] [Related]
20. [Research progress on triptolide functionalized nanoparticulate drug delivery systems for tumor treatment].
Luo YY; Shi JF; Chen L; Li JX; Ma XY; Zhang JM; Geng FN
Zhongguo Zhong Yao Za Zhi; 2019 Nov; 44(21):4566-4572. PubMed ID: 31872649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
